Sumanta Kumar Pal MD
Clinical Professor, Department of Medical Oncology & Therapeutics Research; Co-Director, Kidney Cancer Program, City of Hope, Duarte, CaliforniaBiographical Sketch:
Dr. Sumanta (Monty) Pal is a medical oncologist and an internationally recognized leader in the area of genitourinary cancers. He is a Clinical Professor in the Department of Medical Oncology & Therapeutics Research at City of Hope in Duarte, California, where he is co-director of the kidney cancer program and heads up the kidney and bladder cancer disease team at that institution. Dr. Pal entered medical school at the age of 17, and received his MD from the UCLA School of Medicine, where he developed his interest in cancer research. After residency training in internal medicine at the UCLA Medical Center in Los Angeles, he completed a fellowship in medical oncology at City of Hope Comprehensive Cancer Center, where he has remained on faculty since 2009.
Over that time, he has published more than 400 PubMed-cited articles, which have been featured in prominent journals, including The Lancet, Nature Medicine, Cancer Discovery, Journal of Clinical Oncology, The Lancet Oncology, and European Urology, and has presented his work at numerous international meetings. His goal is to translate laboratory discoveries as quickly and efficiently as possible into tangible benefits for patients. Dr. Pal is the lead investigator on multiple trials, ranging from early phase I experiences to late phase III studies. He has received grants from the National Institute of Health, the Comprehensive Cancer Network, SWOG Cancer Research Network, and multiple other leading entities in support of his research.
Positions:
Clinical Professor, Department of Medical Oncology & Therapeutics Research; Co-Director, Kidney Cancer Program, City of Hope, Duarte, California
Degrees:
MD: UCLA School of Medicine, Los Angeles, California
Postgraduate Training:
Fellowship (hematology/oncology): City of Hope/Harbor-UCLA Medical Center, Los Angeles, California
Research Interests:
Genitourinary cancers; translational science; microbiome
Disclosures
Sumanta Kumar Pal, MD, serves as a consultant to Roche. He also receives institutional research funds from Roche, Genentech, Exelixis, Eisai, and Pfizer.
Recent Contributions to PracticeUpdate:
- ESMO 2018: Immunotherapy in the Neoadjuvant Setting for Bladder Cancer
- ESMO 2018: Cabozantinib in Combination With Atezolizumab for RCC
- ESMO 2018: Radium-223 Plus Abiraterone for Castration-Refractory Prostate Cancer
- ESMO 2018: Practical Implications of New Data on Gynecologic Oncology
- ESMO 2018: Key Data on Bladder Cancer
- ESMO 2018: Comparative Data for Platinum-Sensitive Recurrent Ovarian Cancer
- ESMO 2018: Contextualized New Data on Platinum Resistant Ovarian Cancer
- ESMO 2018: Weekly Paclitaxel Plus Bevacizumab for Relapsed Ovarian Sex Cord Tumors
- ESMO 2018: Clinical Recommendations for Choosing TKIs or Immunotherapy for mRCC
- ESMO 2018: Contextualized Insights From ATLAS on the Use of TKIs in Adjuvant mRCC Treatment